GSA Capital Partners LLP Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

GSA Capital Partners LLP acquired a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 20,819 shares of the biopharmaceutical company’s stock, valued at approximately $108,000.

Several other institutional investors and hedge funds also recently modified their holdings of RVNC. Vanguard Group Inc. lifted its position in shares of Revance Therapeutics by 6.5% during the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after purchasing an additional 328,781 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Revance Therapeutics by 28.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 15,496 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Revance Therapeutics by 9.8% in the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 8,668 shares in the last quarter. Opaleye Management Inc. acquired a new stake in shares of Revance Therapeutics during the first quarter valued at about $3,862,000. Finally, DNB Asset Management AS increased its position in shares of Revance Therapeutics by 25.4% during the second quarter. DNB Asset Management AS now owns 60,229 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 12,201 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

Revance Therapeutics stock opened at $3.80 on Tuesday. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74. The company has a fifty day moving average price of $5.09 and a two-hundred day moving average price of $4.43. The company has a market cap of $398.62 million, a PE ratio of -1.97 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. Equities research analysts anticipate that Revance Therapeutics, Inc. will post -1.54 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on RVNC. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Stifel Nicolaus reduced their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Revance Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.